# Clinical Trials Data ALK - Document 21

# A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

## Clinical Trial: https://clinicaltrials.gov/study/NCT01712217

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Men or women 18 years of age or older\n2. Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib\n3. Measurable disease\n4. Must have been receiving or have received crizotinib\n5. Have adequate cardiac, bone marrow, liver and kidney function\n6. Must be willing and able to provide written informed consent and comply with the protocol and study procedures\n\nExclusion Criteria:\n\n1. Prior anti-cancer treatment with any HSP90 inhibitor\n2. Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug\n3. Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least 3 years\n4. Abnormal heart function\n5. Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors\n6. Hypersensitivity of AT13387 or other components of the drug product\n7. Treatment with an investigational drug within 3 weeks prior to the first dose of study drug\n8. Severe systemic diseases or active uncontrolled infections\n9. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for the clinical trial, a patient with an ALK gene mutation would be eligible to participate. The key criteria supporting their eligibility include:  
  
1. The inclusion criteria specifically state that the patient must have Non-small Cell Lung Cancer with an ALK+ mutation or other mutations potentially sensitive to crizotinib.  
2. The patient must be 18 years or older and have measurable disease.  
3. The patient should have been receiving or have received crizotinib.  
  
As long as the patient meets the inclusion criteria and does not fall under any of the exclusion criteria, they would be eligible for the trial. It's important to ensure that none of the exclusion criteria apply to the patient to confirm their eligibility.